Shareholders owning 97.7% of Stockholm's Wilson Therapeutics AB (publ) accepted Alexion Pharmaceuticals Inc.'s acquisition offer.
Relevant regulatory authorities have also approved the deal, Alexion said in a press release.
Settlement of the tendered shares will occur May 30. The remaining shares may be tendered until June 8, and will be settled June 15. There will be compulsory redemption proceedings and the delisting of Wilson Therapeutics' stock from Nasdaq Stockholm afterward.
The New Haven, Conn.-based biopharmaceutical company had agreed to acquire Wilson Therapeutics for about $855 million, to expand its offering in rare diseases.
